Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. ARS Pharmaceuticals's pretax income for the
three
months ended in Jun. 2026 was $-62.3 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-215.5 Mil.
ARS Pharmaceuticals's pretax margin was -185.21%.
During the past 6 years, ARS Pharmaceuticals's highest Pretax Margin was 9.29%. The lowest was -181216.67%. And the median was -285.50%.
During the past 6 years, ARS Pharmaceuticals's highest Pretax Margin was 9.29%. The lowest was -181216.67%. And the median was -285.50%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals Pre-Tax Income Related Terms
ARS Pharmaceuticals Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for ARS Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPRY vs ALLO, CBIO, IMMX: Pre-Tax Income Comparison
For the Biotechnology subindustry, ARS Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARS Pharmaceuticals Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-215.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals (SPRY) has a Pre-Tax Income of $-215.5 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on ARS Pharmaceuticals and its competitors.
Is ARS Pharmaceuticals' Pre-Tax Income too high?
ARS Pharmaceuticals' current Pre-Tax Income is $-215.5 Mil. Overall, ARS Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' Pre-Tax Income compare to ALLO and CBIO?
ARS Pharmaceuticals' Pre-Tax Income of $-215.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on ARS Pharmaceuticals and its competitors. ARS Pharmaceuticals's current Pre-Tax Income is $-215.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current Pre-Tax Income of $-215.5 Mil. The current Pre-Tax Income is $-215.5 Mil. ARS Pharmaceuticals' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current Pre-Tax Income is $-215.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
26GF Score
Get the complete analysis for SPRY
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRY has been successfully added to your 
